NICE deems MSD’s Keytruda cost-effective as first-line lung cancer therapy
MSD’s Keytruda will be routinely available on the NHS for specific patients with previously untreated metastatic non-small-cell lung cancer, after NHS England struck a deal with the company, endorsed by NICE, to ensure its cost-effectiveness.
Read More
